Oak Ridge Investments LLC grew its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 11.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 98,519 shares of the biopharmaceutical company’s stock after buying an additional 10,338 shares during the period. Oak Ridge Investments LLC’s holdings in Alexion Pharmaceuticals were worth $13,821,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. BlackRock Inc. raised its holdings in shares of Alexion Pharmaceuticals by 7.0% in the second quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock worth $2,424,428,000 after buying an additional 1,298,185 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Alexion Pharmaceuticals by 2.2% during the second quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company’s stock worth $1,798,992,000 after purchasing an additional 318,375 shares during the last quarter. State Street Corp raised its holdings in shares of Alexion Pharmaceuticals by 5.0% during the second quarter. State Street Corp now owns 11,860,647 shares of the biopharmaceutical company’s stock worth $1,443,099,000 after purchasing an additional 561,962 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Alexion Pharmaceuticals by 0.4% during the second quarter. Ameriprise Financial Inc. now owns 6,175,296 shares of the biopharmaceutical company’s stock worth $751,363,000 after purchasing an additional 25,724 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of Alexion Pharmaceuticals by 720.0% during the third quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after purchasing an additional 4,682,336 shares during the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

In other Alexion Pharmaceuticals news, EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the transaction, the executive vice president now owns 26,704 shares in the company, valued at approximately $3,738,560. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,490 shares of company stock valued at $2,337,251. 4.35% of the stock is owned by insiders.

Several analysts recently commented on the stock. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target on the stock in a research report on Tuesday, October 31st. Morgan Stanley restated an “overweight” rating and set a $153.00 price target (up previously from $141.00) on shares of Alexion Pharmaceuticals in a research report on Friday, July 28th. J P Morgan Chase & Co upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the company from $163.00 to $175.00 in a research report on Tuesday, September 5th. Leerink Swann restated an “outperform” rating and set a $182.00 price target (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. They noted that the move was a valuation call. Finally, Stifel Nicolaus dropped their target price on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research report on Tuesday, October 24th. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the company. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average price target of $154.01.

WARNING: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/11/17/alexion-pharmaceuticals-inc-alxn-shares-bought-by-oak-ridge-investments-llc.html.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down $0.01 during midday trading on Friday, reaching $110.33. 2,885,300 shares of the company’s stock traded hands, compared to its average volume of 2,296,870. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. The firm has a market cap of $24,651.02, a PE ratio of 22.56, a PEG ratio of 1.20 and a beta of 1.22.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. During the same quarter in the prior year, the business posted $1.23 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. sell-side analysts predict that Alexion Pharmaceuticals, Inc. will post 4.81 earnings per share for the current year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.